Cepha s.r.o.

At Cepha s.r.o. in Plzen, a major share of the clinical research focuses on bioequivalence and comparative pharmacokinetic studies. These trials mainly involve healthy volunteers and assess whether new formulations perform similarly to established medicines, supporting the development of reliable treatment options.

• Testing antibiotic and anti-infective formulations for conditions such as bacterial infections and influenza
• Comparing medicines used in cardiovascular diseases, including treatments for hypertension and related blood pressure control
• Evaluating oral products for digestive system diseases, including therapies linked to bile and cholesterol-related conditions
• Studying formulations used in metabolic and hormonal diseases, such as type 2 diabetes

These studies help determine whether different products deliver comparable exposure in the body, which is an important step in making medicines more accessible and consistent in everyday care.

The site also conducts trials in cardiovascular diseases and hormonal disorders, with a strong focus on common chronic conditions. Research here examines treatments for high blood pressure, chronic heart failure, chronic kidney disease, and type 2 diabetes mellitus, aiming to improve treatment effectiveness and support better disease control.

• Assessing medicines for hypertension and blood pressure management
• Studying therapies for symptomatic chronic heart failure and related cardiovascular care
• Exploring treatment options for chronic kidney disease in patients with complex metabolic needs
• Evaluating therapies for insufficiently controlled type 2 diabetes mellitus

These clinical trials are designed to help clarify how well established and emerging therapies work in routine use, especially for long-term conditions that require ongoing management.

Another important area of research at the Clinic is immune system diseases and chronic inflammatory disorders. Trials in this field focus on conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, and Crohn’s disease, with the goal of improving symptom control and treatment response.

• Investigating therapies for active rheumatoid arthritis in adults
• Studying treatment options for severe forms of juvenile idiopathic arthritis
• Evaluating approaches for psoriasis and psoriatic arthritis
• Examining medicines for mild-to-moderate Crohn’s disease

These studies aim to find better ways to manage persistent inflammation and improve quality of life for people living with autoimmune and immune-mediated diseases.

Cepha s.r.o. also participates in trials across nervous system diseases and male urogenital diseases, along with studies in sleep disorders. Research topics include Parkinson disease, myasthenia gravis, and short-term insomnia, as well as therapies used in male health and neurological symptom management.

• Evaluating medicines related to Parkinson disease and movement disorders
• Studying treatment options for myasthenia gravis
• Assessing therapies in male urogenital disease and related symptom relief
• Exploring approaches for short-term treatment of insomnia

These trials are intended to support better understanding of how therapies may help with neurological function, sleep quality, and selected urological conditions.

Some research at this research site spans bacterial infections and mycoses, virus diseases, and general health studies in healthy subjects. The site includes work on immune support, infection-related conditions, and safety assessments in volunteers, reflecting a broad interest in both disease-focused and healthy-participant research.

• Studying therapies for recurrent and chronic viral infections in people with reduced immunity
• Evaluating medicines used for infections and influenza
• Conducting research in healthy volunteers to support safety and comparative product assessment
• Exploring treatments connected with immune enhancement and infection prevention

These trials help researchers understand both disease treatment and the performance of medicines in people without active illness, contributing to safer and more effective drug development.